- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Names Highly Cited Researcher 2022 Designations
Nearly 7,000 researchers from across the globe received designations.
Clarivate Plc revealed its 2022 list of Highly Cited Researchers–individuals at universities, research institutes, and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
ISI analysts have awarded Highly Cited Researcher 2022 designations to 6,938 researchers from across the globe who demonstrated significant influence in their chosen field or fields over the last decade. The list spans 69 countries or regions and is spread across a diverse range of research fields in the sciences and social sciences.
Read more about this story here.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
